To our knowledge, α-SMA, and TIMP1/3 have not been identified as O-GlcNAc modified, but have been documented in fibrosis and fibrosis resolution, consistent with our findings (Figure 4), and further underscore a potential benefit of targeting O-GlcNAc in IPF (97, 98). Here, TIMP1 is linked to idiopathic pulmonary fibrosis.